Latest TherOptix News
Jul 21, 2021
July 20, 2021 – Boston – Monty Montoya has been named chief executive officer of TherOptix, a pre-clinical biopharma company focused on delivering clinically impactful therapeutics via a drug-eluding contact lens platform. TherOptix has received orphan drug designation on its lead candidate (001) for prevention of proliferative vitreoretinopathy (PVR). “TherOptix is developing a novel ophthalmic drug delivery platform that has the potential to be a patient game-changer. I look forward to leading this great team through regulatory approval and commercialization,” said Monty Montoya, “TherOptix will offer patients the safest and most efficacious way for critical medicines to be delivered to the front and back of the eye.” Shared by Tyler Stowater, board member of TherOptix, Inc.